Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Habermann

Showing results (41-50 of 374) with videos related to

Pageof 38
Sort By:
Leukemia & Lymphoma|June 22, 2019
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphomaHeather A Personett, Erin F Barreto, Kristen B McCullough, et al.
Hematological Oncology|March 22, 2023
Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysisVanja Zeremski, Ellen D McPhail, Thomas M Habermann, et al.
American Journal of Hematology|January 7, 2009
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
International Journal of Cancer|July 17, 2003
Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphomaJames R Cerhan, Kristin E Anderson, Carol A Janney, et al.
American Journal of Hematology|June 23, 2015
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011Mohammed Al-Hamadani, Thomas M Habermann, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphomaWilliam G Martin, Kay M Ristow, Thomas M Habermann, et al.
American Journal of Hematology|June 6, 2008
mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)Shernan G Holtan, Luis F Porrata, Joseph P Colgan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2010
Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphomaThorvardur R Halfdanarson, Alberto Rubio-Tapia, Kay M Ristow, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|May 17, 2021
Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always InfectionGordon J Ruan, Sangeetha Gandhi, Jithma P Abeykoon, et al.
The Oncologist|August 12, 2017
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma ProjectDaniel J Sargent, Qian Shi, Christopher R Flowers, et al.
Pageof 38

Showing results (41-50 of 374) with videos related to

Sort By:
Pageof 38
Leukemia & Lymphoma|June 22, 2019
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphomaHeather A Personett, Erin F Barreto, Kristen B McCullough, et al.
Hematological Oncology|March 22, 2023
Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysisVanja Zeremski, Ellen D McPhail, Thomas M Habermann, et al.
American Journal of Hematology|January 7, 2009
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
International Journal of Cancer|July 17, 2003
Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphomaJames R Cerhan, Kristin E Anderson, Carol A Janney, et al.
American Journal of Hematology|June 23, 2015
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011Mohammed Al-Hamadani, Thomas M Habermann, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphomaWilliam G Martin, Kay M Ristow, Thomas M Habermann, et al.
American Journal of Hematology|June 6, 2008
mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)Shernan G Holtan, Luis F Porrata, Joseph P Colgan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2010
Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphomaThorvardur R Halfdanarson, Alberto Rubio-Tapia, Kay M Ristow, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|May 17, 2021
Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always InfectionGordon J Ruan, Sangeetha Gandhi, Jithma P Abeykoon, et al.
The Oncologist|August 12, 2017
The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma ProjectDaniel J Sargent, Qian Shi, Christopher R Flowers, et al.
Pageof 38